MX394605B - Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. - Google Patents

Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Info

Publication number
MX394605B
MX394605B MX2017016681A MX2017016681A MX394605B MX 394605 B MX394605 B MX 394605B MX 2017016681 A MX2017016681 A MX 2017016681A MX 2017016681 A MX2017016681 A MX 2017016681A MX 394605 B MX394605 B MX 394605B
Authority
MX
Mexico
Prior art keywords
chloroquine
treatment
inflammatory
clemizol
compounds
Prior art date
Application number
MX2017016681A
Other languages
English (en)
Other versions
MX2017016681A (es
Inventor
Edward A Pham
Jeffrey S Glenn
Original Assignee
Eiger Group Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Group Int Inc filed Critical Eiger Group Int Inc
Publication of MX2017016681A publication Critical patent/MX2017016681A/es
Publication of MX394605B publication Critical patent/MX394605B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen en la presente métodos para uso de R-cloroquina o clemizol o combinaciones de R-cloroquina y clemizol para el tratamiento de un sujeto que necesita del mismo. Los métodos incluyen métodos de tratamiento de afecciones inflamatorias, tratamiento de cáncer hepático o reducción del riesgo de desarrollar cáncer hepático en un sujeto. Los usos también incluyen métodos de tratamiento de esteatohepatitis no alcohólica en un sujeto.
MX2017016681A 2015-06-30 2016-06-30 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. MX394605B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
PCT/US2016/040566 WO2017004454A1 (en) 2015-06-30 2016-06-30 Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Publications (2)

Publication Number Publication Date
MX2017016681A MX2017016681A (es) 2018-07-06
MX394605B true MX394605B (es) 2025-03-24

Family

ID=57609247

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017016681A MX394605B (es) 2015-06-30 2016-06-30 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2023003792A MX2023003792A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2022008100A MX2022008100A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023003792A MX2023003792A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2022008100A MX2022008100A (es) 2015-06-30 2017-12-18 Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.

Country Status (14)

Country Link
US (3) US10688083B2 (es)
EP (1) EP3317274A4 (es)
JP (3) JP7068827B2 (es)
KR (2) KR20180032578A (es)
CN (2) CN107922404B (es)
AU (4) AU2016288699B2 (es)
CA (2) CA3178499A1 (es)
HK (1) HK1249508A1 (es)
IL (4) IL310969A (es)
MX (3) MX394605B (es)
NZ (1) NZ776616A (es)
TW (3) TWI771272B (es)
WO (1) WO2017004454A1 (es)
ZA (2) ZA201708471B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7068827B2 (ja) * 2015-06-30 2022-05-17 アイガー グループ インターナショナル インコーポレイテッド 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
CA3082591A1 (en) * 2017-11-15 2019-05-23 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
CN115515935B (zh) * 2020-04-30 2025-01-07 中美华世通生物医药科技(武汉)股份有限公司 冠状病毒感染的治疗或预防
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) * 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
JP2006517969A (ja) 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
CN1761478A (zh) * 2003-02-14 2006-04-19 康宾纳特克斯公司 治疗免疫炎性疾病的联合疗法
AU2003219160A1 (en) * 2003-03-12 2004-09-30 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
JP5846711B2 (ja) * 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
JP2009526070A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
EP2203168B1 (en) * 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US20100285001A1 (en) * 2007-10-02 2010-11-11 University Of Rochester Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
CA3184380A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
DK2460403T3 (da) 2009-07-31 2019-08-19 Smc Global Asset Inc Steatohepatitis lever cancer model mus
KR102122267B1 (ko) * 2009-08-14 2020-06-12 레비비코르 인코포레이션 당뇨병 치료를 위한 복수 형질전환 돼지
WO2011041311A2 (en) 2009-09-29 2011-04-07 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
EP2488180A4 (en) * 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8658787B2 (en) * 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
EP2818473A4 (en) 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20130273003A1 (en) 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
BR112014029115A8 (pt) * 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
TW201402556A (zh) * 2012-05-30 2014-01-16 Toyama Chemical Co Ltd 氘化含氮雜環羧醯胺衍生物或其鹽
WO2014031769A2 (en) * 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
JP7068827B2 (ja) * 2015-06-30 2022-05-17 アイガー グループ インターナショナル インコーポレイテッド 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Also Published As

Publication number Publication date
US20240398761A1 (en) 2024-12-05
TW202317103A (zh) 2023-05-01
MX2023003792A (es) 2023-04-26
TW201717941A (zh) 2017-06-01
JP2018519340A (ja) 2018-07-19
IL279020B2 (en) 2023-07-01
EP3317274A4 (en) 2019-05-08
TWI830262B (zh) 2024-01-21
BR112017028601A2 (pt) 2018-08-28
IL279020B1 (en) 2023-03-01
US20210052553A1 (en) 2021-02-25
CA3178499A1 (en) 2017-01-05
IL300476A (en) 2023-04-01
IL300476B1 (en) 2024-03-01
CN113274386A (zh) 2021-08-20
US10688083B2 (en) 2020-06-23
WO2017004454A8 (en) 2018-01-25
US20180200228A1 (en) 2018-07-19
AU2021201234A1 (en) 2021-03-11
JP7470151B2 (ja) 2024-04-17
AU2023201397A1 (en) 2023-04-06
MX2017016681A (es) 2018-07-06
CN107922404A (zh) 2018-04-17
NZ776616A (en) 2024-11-29
CA2989634A1 (en) 2017-01-05
NZ738291A (en) 2021-06-25
TWI881480B (zh) 2025-04-21
EP3317274A1 (en) 2018-05-09
KR20180032578A (ko) 2018-03-30
CA2989634C (en) 2022-12-06
AU2016288699A1 (en) 2018-01-18
IL300476B2 (en) 2024-07-01
KR20230129590A (ko) 2023-09-08
HK1249508A1 (zh) 2018-11-02
AU2016288699B2 (en) 2020-11-26
MX2022008100A (es) 2022-07-11
TWI771272B (zh) 2022-07-21
US12090141B2 (en) 2024-09-17
ZA201708471B (en) 2022-05-25
JP2024083475A (ja) 2024-06-21
WO2017004454A1 (en) 2017-01-05
IL279020A (es) 2020-12-31
IL310969A (en) 2024-04-01
JP2022105149A (ja) 2022-07-12
AU2024266943A1 (en) 2024-12-19
AU2023201397B2 (en) 2024-10-03
TW202402283A (zh) 2024-01-16
IL256233A (en) 2018-02-28
JP7068827B2 (ja) 2022-05-17
ZA202004136B (en) 2025-08-27
CN107922404B (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
MX394605B (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
EA202091540A1 (ru) Антитела к lilrb2
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
IL269150A (en) Compositions and methods for treating cancer
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX379270B (es) Composiciones que comprenden cepas bacterianas.
PL3943093T3 (pl) Zastosowanie pasteryzowanej akkermansia do leczenia nowotworu złośliwego
IL268814A (en) Compositions and methods for treatment of cancer
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
PT3377516T (pt) Composição para o tratamento do cancro
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
DK3624837T3 (da) Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
PT3773738T (pt) Conjugados anticorpos-fármaco e suas utilizações para o tratamento do cancro
PL3490560T3 (pl) Niraparyb do stosowania w sposobie leczenia nowotworu prostaty
IL269157A (en) Compositions and methods for treating cancer
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
LT3532067T (lt) Liposominė vaisto forma, skirta naudoti gydant vėžį
HUE055132T2 (hu) Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
PL3478284T3 (pl) Związki i kompozycje do leczenia nowotworu złośliwego
DK3383872T3 (da) 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling